In compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Indoco Remedies has informed that a meeting of the Board of Directors will be held on Wednesday June 24, 2020 to consider and approve, the unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31st March 2020, the Audited Standalone and Consolidated Financial results for the year ended 31st March, 2020, and recommendation of Dividend, if any, for the Financial Year 2019-2020. Further note that in terms of the Company’s Code of Conduct for Prevention of Insider Trading, the ‘Trading Window’ for dealing in the securities of the Company has been closed from April 1, 2020 to June 26, 2020.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: